<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SULFATRIM- sulfamethoxazole and trimethoprimÂ suspensionÂ </strong><br>Actavis Mid Atlantic LLC<br></p></div>
<h1>
<span class="Bold">SULFAMETHOXAZOLE AND TRIMETHOPRIM ORAL SUSPENSION USP</span><span class="Bold"><br></span><br>
FORM NO. 1284/1285<br>
Rev. 3/06 <br>
VC2785</h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx Only</span></p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of Sulfamethoxazole and Trimethoprim Oral Suspension and other antibacterial drugs, Sulfamethoxazole and Trimethoprim Oral Suspension should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.<br></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-3"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Sulfamethoxazole and Trimethoprim Oral Suspension is a synthetic antibacterial combination product.</p>
<p>Sulfamethoxazole is N<span class="Sup">1</span>-(5-methyl-3- isoxazolyl) sulfanilamide. It is an almost white, odorless, tasteless compound with a molecular weight of 253<span class="Bold">.</span>28 and the following structural formula:</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=A8DF90D8-78B3-48C3-B42E-1E651D81454B&amp;name=current-tmp200912115380800.jpg"></div>
<p>Trimethoprim is 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine. It is a white to light yellow, odorless, bitter compound with a molecular weight of 290<span class="Bold">.</span>32, and the following structural formula:</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=A8DF90D8-78B3-48C3-B42E-1E651D81454B&amp;name=current-tmp200912115380941.jpg"></div>
<p><span class="Bold">EACH 5 mL (ONE TEASPOONFUL) OF SULFAMETHOXAZOLE AND TRIMETHOPRIM ORAL SUSPENSION USP CONTAINS </span>200 mg sulfamethoxazole and 40 mg trimethoprim.</p>
<p><span class="Bold">INACTIVE INGREDIENTS: </span>alcohol (less than 0<span class="Bold">.</span>5%), carboxymethylcellulose sodium, citric acid, FD&amp;C Red #40, FD&amp;C Yellow #6, flavor, methylparaben, microcrystalline cellulose and carboxymethylcellulose sodium, polysorbate 80, propylene glycol, propylparaben, purified water, saccharin sodium, simethicone emulsion, sucrose.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-4"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Sulfamethoxazole and Trimethoprim Oral Suspension is rapidly absorbed following oral administration. Both sulfamethoxazole and trimethoprim exist in the blood as unbound, protein-bound and metabolized forms; sulfamethoxazole also exists as the conjugated form. The metabolism of sulfamethoxazole occurs predominately by N<span class="Sub">4</span>-acetylation, although the glucuronide conjugate has been identified. The principal metabolites of trimethoprim are the 1 - and 3 - oxides and the 3' - and 4' â€“ hydroxy derivatives. The free forms of sulfamethoxazole and trimethoprim are considered to be the therapeutically active forms. Approximately 70% of sulfamethoxazole and 44% of trimethoprim are bound to plasma proteins. The presence of 10 mg percent sulfamethoxazole in plasma decreases the protein binding of trimethoprim by an insignificant degree; trimethoprim does not influence the protein binding of sulfamethoxazole.</p>
<p>Peak blood levels for the individual components occur 1 to 4 hours after oral administration. The mean serum half-lives of sulfamethoxazole and trimethoprim are 10 and 8 to 10 hours, respectively. However, patients with severely <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> exhibit an increase in the half-lives of both components, requiring dosage regimen adjustment (see <a href="#A590B1C4-4FA8-4D29-ABC3-5B0CCF98DBF3">DOSAGE AND ADMINISTRATION</a> section). Detectable amounts of sulfamethoxazole and trimethoprim are present in the blood 24 hours after drug administration. During administration of 800 mg sulfamethoxazole and 160 mg trimethoprim b.i.d., the mean steady-state plasma concentration of trimethoprim was 1<span class="Bold">.</span>72 Î¼g/mL. The steady-state mean plasma levels of free and total sulfamethoxazole were 57<span class="Bold">.</span>4 Î¼g/mL and 68<span class="Bold">.</span>0 Î¼g/mL, respectively. These steady-state levels were achieved after three days of drug administration.<span class="Sup">1</span></p>
<p>Excretion of sulfamethoxazole and trimethoprim is primarily by the kidneys through both glomerular filtration and tubular secretion. Urine concentrations of both sulfamethoxazole and trimethoprim are considerably higher than are the concentrations in the blood. The average percentage of the dose recovered in urine from 0 to 72 hours after a single oral dose is 84<span class="Bold">.</span>5% for total sulfonamide and 66<span class="Bold">.</span>8% for free trimethoprim. Thirty percent of the total sulfonamide is excreted as free sulfamethoxazole, with the remaining as N<span class="Sub">4</span>-acetylated metabolite.<span class="Sup">2</span> When administered together, neither sulfamethoxazole nor trimethoprim affects the urinary excretion pattern of the other.</p>
<p>Both sulfamethoxazole and trimethoprim distribute to <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span>, vaginal fluid, and middle ear fluid; trimethoprim also distributes to bronchial secretion, and both pass the placental barrier and are excreted in breast milk.</p>
<p>Microbiology<span class="Bold">: </span>Sulfamethoxazole inhibits bacterial synthesis of dihydrofolic acid by competing with <span class="Italics">para</span>-aminobenzoic acid (PABA). Trimethoprim blocks the production of tetrahydrofolic acid from dihydrofolic acid by binding to and reversibly inhibiting the required enzyme,</p>
<p>dihydrofolate reductase. Thus, this combination blocks two consecutive steps in the biosynthesis of nucleic acids and proteins essential to many bacteria.</p>
<p><span class="Italics">In vitro </span>studies have shown that <span class="product-label-link" type="condition" conceptid="4207042" conceptname="Viral resistance">bacterial resistance</span> develops more slowly with this combination than with either sulfamethoxazole or trimethoprim alone.</p>
<p><span class="Italics">In vitro </span>serial dilution tests have shown that the spectrum of antibacterial activity of sulfamethoxazole and trimethoprim includes the common urinary tract pathogens with the exception of <span class="Italics">Pseudomonas aeruginosa</span>. The following organisms are usually susceptible: <span class="Italics">Escherichia coli</span>, <span class="Italics">Klebsiella </span>species, <span class="Italics">Enterobacter </span>species, <span class="Italics">Morganella morganii</span>, <span class="Italics">Proteus mirabilis </span>and indole-positive <span class="Italics">Proteus </span>species including <span class="Italics">Proteus vulgaris</span>. The usual spectrum of antimicrobial activity of sulfamethoxazole and trimethoprim includes the following bacterial pathogens isolated from middle ear exudate and from bronchial secretions: <span class="Italics">Haemophilus influenzae</span>, including ampicillin-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>, and <span class="Italics">Streptococcus pneumoniae</span>. <span class="Italics">Shigella flexneri </span>and <span class="Italics">Shigella sonnei </span>are usually susceptible. The usual spectrum also includes enterotoxigenic <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Escherichia coli </span>(ETEC) causing bacterial <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>.</p>
<table frame="void">
<thead>
<tr class="First"><th align="center" colspan="5" valign="middle">
<span class="Bold">REPRESENTATIVE <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">MINIMUM INHIBITORY CONCENTRATION</span> VALUES</span><span class="Bold"><br></span><span class="Bold">FOR SULFAMETHOXAZOLE AND TRIMETHOPRIM SUSCEPTIBLE ORGANISMS</span><span class="Bold"><br></span><span class="Bold">(MIC-Î¼g/mL)</span>
</th></tr>
<tr>
<td align="left" rowspan="2" valign="middle"><span class="Bold">Bacteria</span></td>
<td align="center" rowspan="2" valign="top">
<span class="Bold">TMP </span><span class="Bold"><br></span><span class="Bold">Alone</span>
</td>
<td align="center" rowspan="2" valign="top">
<span class="Bold">SMX </span><span class="Bold"><br></span><span class="Bold">Alone</span>
</td>
<th align="center" colspan="2" valign="top"><span class="Bold">TMP/SMX (1:20)</span></th>
</tr>
<tr class="Last">
<td align="center" valign="top"><span class="Bold">TMP</span></td>
<td align="center" valign="top"><span class="Bold">SMX</span></td>
</tr>
</thead>
<tfoot><tr class="First Last"><td align="left" colspan="5" valign="top">TMP = Trimethoprim; SMX = Sulfamethoxazole<br>â€ Rudoy RC, Nelson JD, Haltalin KC, <span class="Italics">Antimicrob Agents Chemother. </span>May 1974:5:439-443.</td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left" valign="top"><span class="Italics">Escherichia coli</span></td>
<td align="center" valign="top">0.05-1.5</td>
<td align="center" valign="top">1.0-245</td>
<td align="center" valign="top">0.05-0.5</td>
<td align="center" valign="top">0.95-9.5</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Escherichia coli</span><span class="Italics"><br></span>(enterotoxigenic <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</td>
<td align="center" valign="bottom">0.015-0.15</td>
<td align="center" valign="bottom">0.285-&gt;950</td>
<td align="center" valign="bottom">0.005-0.15</td>
<td align="center" valign="bottom">0.095-2.85</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Proteus </span>species<br>(indole positive)</td>
<td align="center" valign="bottom">0.5-5.0</td>
<td align="center" valign="bottom">7.35-300</td>
<td align="center" valign="bottom">0.05-1.5</td>
<td align="center" valign="bottom">0.95-28.5</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Morganella</span><span class="Italics"><br></span><span class="Italics">morganii</span>
</td>
<td align="center" valign="bottom">0.5-5.0</td>
<td align="center" valign="bottom">7.35-300</td>
<td align="center" valign="bottom">0.05-1.5</td>
<td align="center" valign="bottom">0.95-28.5</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Proteus</span><span class="Italics"><br></span><span class="Italics">mirabilis</span>
</td>
<td align="center" valign="bottom">0.5-1.5</td>
<td align="center" valign="bottom">7.35-30</td>
<td align="center" valign="bottom">0.05-0.15</td>
<td align="center" valign="bottom">0.95-2.85</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Klebsiella</span><span class="Italics"><br></span>species</td>
<td align="center" valign="bottom">0.15-5.0</td>
<td align="center" valign="bottom">2.45-245</td>
<td align="center" valign="bottom">0.05-1.5</td>
<td align="center" valign="bottom">0.95-28.5</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Enterobacter</span><span class="Italics"><br></span>species</td>
<td align="center" valign="bottom">0.15-5.0</td>
<td align="center" valign="bottom">2.45-245</td>
<td align="center" valign="bottom">0.05-1.5</td>
<td align="center" valign="bottom">0.95-28.5</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Haemophilus</span><span class="Italics"><br></span><span class="Italics">influenzae</span>
</td>
<td align="center" valign="bottom">0.15-1.5</td>
<td align="center" valign="bottom">2.85-95</td>
<td align="center" valign="bottom">0.015-0.15</td>
<td align="center" valign="bottom">0.285-2.85</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Streptococcus</span><span class="Italics"><br></span><span class="Italics">pneumoniae</span>
</td>
<td align="center" valign="bottom">0.15-1.5</td>
<td align="center" valign="bottom">7.35-24.5</td>
<td align="center" valign="bottom">0.05-0.15</td>
<td align="center" valign="bottom">0.95-2.85</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Shigella</span><span class="Italics"><br></span><span class="Italics">flexneriâ€ </span>
</td>
<td align="center" valign="bottom">&lt;0.01-0.04</td>
<td align="center" valign="bottom">&lt;0.16-&gt;320</td>
<td align="center" valign="bottom">&lt;0.002-0.03</td>
<td align="center" valign="bottom">0.04-0.625</td>
</tr>
<tr class="Last">
<td align="left" valign="top">
<span class="Italics">Shigella</span><span class="Italics"><br></span><span class="Italics">sonneiâ€ </span>
</td>
<td align="center" valign="bottom">0.02-0.08</td>
<td align="center" valign="bottom">0.625-&gt;320</td>
<td align="center" valign="bottom">0.004-0.06</td>
<td align="center" valign="bottom">0.08-1.25</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Susceptibility Testing</span>:</p>
<p>The recommended quantitative disc susceptibility method may be used for estimating the susceptibility of bacteria to sulfamethoxazole and trimethoprim.<span class="Sup">3,4</span> With this procedure, a report from the laboratory of â€œSusceptible to trimethoprim and sulfamethoxazoleâ€? indicates that the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is likely to respond to therapy with this product. If the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is confined to the urine, a report of â€œIntermediate susceptibility to trimethoprim and sulfamethoxazoleâ€? also indicates that the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is likely to respond. A report of â€œResistant to trimethoprim and sulfamethoxazoleâ€? indicates that the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is unlikely to respond to therapy with this product.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="A51BD75B-2683-44F8-A674-2CCF7E76019E"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of Sulfamethoxazole and Trimethoprim Oral Suspension and other antibacterial drugs, Sulfamethoxazole and Trimethoprim Oral Suspension should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span>:</span></p>
<p>For the treatment of <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> due to susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following organisms: <span class="Italics">Escherichia coli</span>, <span class="Italics">Klebsiella </span>species, <span class="Italics">Enterobacter </span>species, <span class="Italics">Morganella morganii</span>, <span class="Italics">Proteus mirabilis </span>and <span class="Italics">Proteus vulgaris</span>. It is recommended that initial episodes of uncomplicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> be treated with a single effective antibacterial agent rather than the combination.</p>
<div class="Section">
<a name="section-5.1"></a><p></p>
<h2>Acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span>:</h2>
<div class="Section">
<a name="section-5.1.1"></a><p></p>
<h3>For the treatment of acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> in children due to susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician this combination offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim in children under two years of age. This product is not indicated for <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> or prolonged administration in <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> at any age.</h3>
<p class="First"><span class="Bold">Acute Exacerbations Of <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">Chronic Bronchitis</span> In Adults: </span></p>
<p>For the treatment of acute exacerbations of <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span> due to susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Streptococcus pneumoniae </span>or <span class="Italics">Haemophilus influenzae </span>when in the judgment of the physician, this combination offers some advantage over the use of a single antimicrobial agent.</p>
<p><span class="Bold">Shigellosis: </span></p>
<p>For the treatment of <span class="product-label-link" type="condition" conceptid="201773" conceptname="Enteritis of small intestine">enteritis</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Shigella flexneri </span>and <span class="Italics">Shigella sonnei </span>when antibacterial therapy is indicated.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="438350" conceptname="Pneumocystosis">Pneumocystis Carinii Pneumonia</span>: </span></p>
<p>For the treatment of documented <span class="Italics">Pneumocystis carinii </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>. For prophylaxis against <span class="Italics">Pneumocystis carinii </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> in individuals who are immunosuppressed and considered to be at an increased risk of developing <span class="Italics">Pneumocystis carinii </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>.</p>
<p><span class="Bold">Travelersâ€™ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> In Adults: </span></p>
<p>For the treatment of travelersâ€™ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> due to susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of enterotoxigenic <span class="Italics">E. coli.</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="A12BDBCA-EBC7-4C63-A38B-E62F5C1CBE79"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Sulfamethoxazole and Trimethoprim Oral Suspension is contraindicated in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to trimethoprim or sulfonamides and in patients with documented <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span> due to <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folate deficiency</span>. Sulfamethoxazole and Trimethoprim Oral Suspension is also contraindicated in pregnant patients and nursing mothers, because sulfonamides pass the placenta and are excreted in the milk and may cause <span class="product-label-link" type="condition" conceptid="4326231" conceptname="Kernicterus">kernicterus</span>. Sulfamethoxazole and Trimethoprim Oral Suspension is contraindicated in infants less than 2 months of age.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="A5DE02F3-B0B8-4298-B53B-8C4CD4D9D660"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold">FATALITIES ASSOCIATED WITH THE ADMINISTRATION OF SULFONAMIDES, ALTHOUGH RARE, HAVE OCCURRED DUE TO SEVERE REACTIONS, INCLUDING <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">STEVENS-JOHNSON SYNDROME</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">TOXIC EPIDERMAL NECROLYSIS</span>, FULMINANT <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">HEPATIC NECROSIS</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">AGRANULOCYTOSIS</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">APLASTIC ANEMIA</span> AND OTHER <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">BLOOD DYSCRASIAS</span>. </span></p>
<p><span class="Bold">SULFAMETHOXAZOLE AND TRIMETHOPRIM ORAL SUSPENSION SHOULD BE DISCONTINUED AT THE FIRST APPEARANCE OF <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">SKIN RASH</span> OR ANY SIGN OF ADVERSE REACTION. </span>Clinical signs, such as <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span> or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> may be early indications of serious reactions. In rare instances a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> may be followed by more severe reactions, such as <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> or serious <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood disorder</span>. Complete blood counts should be done frequently in patients receiving sulfonamides.</p>
<p><span class="Bold">SULFAMETHOXAZOLE AND TRIMETHOPRIM ORAL SUSPENSION SHOULD NOT BE USED IN THE TREATMENT OF <span class="product-label-link" type="condition" conceptid="28060" conceptname="Streptococcal sore throat">STREPTOCOCCAL PHARYNGITIS</span>.</span> Clinical studies have documented that patients with group A Î²-hemolytic streptococcal tonsillopharyngitis have a greater incidence of bacteriologic failure when treated with this combination than do those patients treated with penicillin, as evidenced by failure to eradicate this organism from the tonsillopharyngeal area.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-8.1"></a><p></p>
<h2>General</h2>
<p class="First">Prescribing Sulfamethoxazole and Trimethoprim Oral Suspension in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
<p>Sulfamethoxazole and Trimethoprim Oral Suspension should be given with caution to patients with impaired renal or hepatic function, to those with possible <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folate deficiency</span> (e.g., the elderly, chronic alcoholics, patients receiving anticonvulsant therapy, patients with <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption syndrome</span>, and patients in <span class="product-label-link" type="condition" conceptid="4090739" conceptname="Nutritional disorder">malnutrition</span> states) and to those with severe allergies or bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. In glucose-6-phosphate dehydrogenase deficient individuals, <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> may occur. This reaction is frequently dose-related.</p>
</div>
<div class="Section">
<a name="section-8.2"></a><p></p>
<h2>Use In The Elderly:</h2>
<p class="First">There may be an increased risk of severe adverse reactions in elderly patients, particularly when complicating conditions exist, e.g., impaired kidney and/or liver function, or concomitant use of other drugs. Severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, generalized bone marrow suppression (see <a href="#A5DE02F3-B0B8-4298-B53B-8C4CD4D9D660">WARNINGS</a> and <a href="#A6C7F89B-8E6F-4242-B369-00DC725445CC">ADVERSE REACTIONS</a> sections) or a specific decrease in platelets (with or without <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>) are the most frequently reported severe adverse reactions in elderly patients. In those concurrently receiving certain diuretics, primarily thiazides, an increased incidence of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> with <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span> has been reported. Appropriate dosage adjustments should be made for patients with impaired kidney function (see <a href="#A590B1C4-4FA8-4D29-ABC3-5B0CCF98DBF3">DOSAGE AND ADMINISTRATION section</a>).</p>
<p><span class="Bold">Use In The Treatment Of And Prophylaxis For <span class="product-label-link" type="condition" conceptid="438350" conceptname="Pneumocystosis">Pneumocystis Carinii Pneumonia</span> In Patients With <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">Acquired Immunodeficiency Syndrome</span> (AIDS): </span></p>
<p>AIDS patients may not tolerate or respond to sulfamethoxazole and trimethoprim oral suspension in the same manner as non-AIDS patients. The incidence of side effects, particularly <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> and elevated aminotransferase (transaminase) values with sulfamethoxazole and trimethoprim therapy in AIDS patients who are being treated for <span class="Italics">Pneumocystic carinii </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> has been reported to be greatly increased compared with the incidence normally associated with the use of sulfamethoxazole and trimethoprim in non-AIDS patients. Adverse effects are generally less severe in patients receiving sulfamethoxazole and trimethoprim for prophylaxis. A history of mild intolerance to sulfamethoxazole and trimethoprim in AIDS patients does not appear to predict intolerance of subsequent secondary prophylaxis.<span class="Sup">5</span> However, if a patient develops <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or any sign of adverse reaction, therapy with sulfamethoxazole and trimethoprim oral suspension should be reevaluated (see <a href="#A5DE02F3-B0B8-4298-B53B-8C4CD4D9D660">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-8.3"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be counseled that antibacterial drugs including Sulfamethoxazole and Trimethoprim Oral Suspension should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When Sulfamethoxazole and Trimethoprim Oral Suspension is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Sulfamethoxazole and Trimethoprim Oral Suspension or other antibacterial drugs in the future.</p>
<p>Patients should be instructed to maintain an adequate fluid intake in order to prevent <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span> and stone formation.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-8.4"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Complete blood counts should be done frequently in patients receiving sulfamethoxazole and trimethoprim; if a significant reduction in the count of any formed blood element is noted, this drug product should be discontinued. Urinalysis with careful microscopic examination and renal function tests should be performed during therapy, particularly for those patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-8.5"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">In elderly patients concurrently receiving certain diuretics, primarily thiazides, an increased incidence of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> with <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span> has been reported.</p>
<p>It has been reported that sulfamethoxazole and trimethoprim may prolong the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time in patients who are receiving the anticoagulant warfarin. This interaction should be kept in mind when sulfamethoxazole and trimethoprim oral suspension is given to patients already on anticoagulant therapy, and the coagulation time should be reassessed.</p>
<p>Sulfamethoxazole and trimethoprim may inhibit the hepatic metabolism of phenytoin. Sulfamethoxazole and trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 39% and decreased the phenytoin metabolic clearance rate by 27%. When administering these drugs concurrently, one should be alert for possible excessive phenytoin effect.</p>
<p>Sulfonamides can also displace methotrexate from plasma protein binding sites, thus increasing free methotrexate concentrations.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-8.6"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">This combination product, specifically the trimethoprim component, can interfere with a serum methotrexate assay as determined by the competitive binding protein technique (CBPA) when a bacterial dihydrofolate reductase is used as the binding protein. No interference occurs, however, if methotrexate is measured by a radioimmunoassay (RIA).</p>
<p>The presence of sulfamethoxazole and trimethoprim may also interfere with the JaffÃ© alkaline picrate reaction assay for creatinine, resulting in overestimations of about 10% in the range of normal values.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-8.7"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section">
<a name="section-8.7.1"></a><p></p>
<h3>Carcinogenesis:</h3>
<p class="First">Long-term studies in animals to evaluate carcinogenic potential have not been conducted with sulfamethoxazole and trimethoprim.</p>
</div>
<div class="Section">
<a name="section-8.7.2"></a><p></p>
<h3>Mutagenesis:</h3>
<p class="First">Bacterial mutagenic studies have not been performed with sulfamethoxazole and trimethoprim in combination. Trimethoprim was demonstrated to be nonmutagenic in the Ames assay. No chromosomal damage was observed in human leukocytes in vitro with sulfamethoxazole and trimethoprim alone or in combination; the concentrations used exceeded blood levels of these compounds following therapy with sulfamethoxazole and trimethoprim. Observations of leukocytes obtained from patients treated with sulfamethoxazole and trimethoprim revealed no chromosomal abnormalities.</p>
</div>
<div class="Section">
<a name="section-8.7.3"></a><p></p>
<h3>Impairment Of Fertility:</h3>
<p class="First">No adverse effects on fertility or general reproductive performance were observed in rats given oral dosages as high as 70 mg/kg/day trimethoprim plus 350 mg/kg/day sulfamethoxazole.</p>
</div>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.8"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.8.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<p class="First">Pregnancy Category C<span class="Italics">.</span> In rats, oral doses of 533 mg/kg sulfamethoxazole or 200 mg/kg trimethoprim produced teratological effects manifested mainly as <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palates</span>.</p>
<p>The highest dose which did not cause <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palates</span> in rats was 512 mg/kg sulfamethoxazole or 192 mg/kg trimethoprim when administered separately. In two studies in rats, no teratology was observed when 512 mg/kg of sulfamethoxazole was used in combination with 128 mg/kg of trimethoprim. In one study, however, <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palates</span> were observed in one litter out of 9 when 355 mg/kg of sulfamethoxazole was used in combination with 88 mg/kg of trimethoprim.</p>
<p>In some rabbit studies, an overall increase in fetal loss (dead and resorbed and malformed conceptuses) was associated with doses of trimethoprim 6 times the human therapeutic dose.</p>
<p>While there are no large, well-controlled studies on the use of sulfamethoxazole and trimethoprim in pregnant women, Brumfitt and Pursell<span class="Sup">6</span>, in a retrospective study, reported the outcome of 186 pregnancies during which the mother received either placebo or sulfamethoxazole and trimethoprim. The incidence of congenital abnormalities was 4<span class="Bold">.</span>5% (3 of 66) in those who received placebo and 3<span class="Bold">.</span>3% (4 of 120) in those receiving sulfamethoxazole and trimethoprim. There were no abnormalities in the 10 children whose mothers received the drug during the first trimester. In a separate survey, Brumfitt and Pursell also found no congenital abnormalities in 35 children whose mothers had received oral sulfamethoxazole and trimethoprim at the time of conception or shortly thereafter.</p>
<p>Because sulfamethoxazole and trimethoprim may interfere with folic acid metabolism, this product should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="section-8.8.2"></a><p></p>
<h3>Nonteratogenic Effects</h3>
<p class="First">See <a href="#A12BDBCA-EBC7-4C63-A38B-E62F5C1CBE79">CONTRAINDICATIONS</a> section.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.9"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">See <a href="#A12BDBCA-EBC7-4C63-A38B-E62F5C1CBE79">CONTRAINDICATIONS</a> section.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.10"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Sulfamethoxazole and Trimethoprim Oral Suspension is not recommended for pediatric patients younger than 2 months of age (see <a href="#A51BD75B-2683-44F8-A674-2CCF7E76019E">INDICATIONS AND USAGE</a> and <a href="#A12BDBCA-EBC7-4C63-A38B-E62F5C1CBE79">CONTRAINDICATIONS</a> sections).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="A6C7F89B-8E6F-4242-B369-00DC725445CC"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The most common adverse effects are <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span> (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>) and <span class="product-label-link" type="condition" conceptid="4070025" conceptname="Cutaneous hypersensitivity">allergic skin reactions</span> (such as <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>). <span class="Bold">FATALITIES ASSOCIATED WITH THE ADMINISTRATION OF SULFONAMIDES, ALTHOUGH RARE, HAVE OCCURRED DUE TO SEVERE REACTIONS, INCLUDING <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">STEVENS-JOHNSON SYNDROME</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">TOXIC EPIDERMAL NECROLYSIS</span>, FULMINANT <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">HEPATIC NECROSIS</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">AGRANULOCYTOSIS</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">APLASTIC ANEMIA</span> AND OTHER <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">BLOOD DYSCRASIAS</span> (SEE</span><a href="#A5DE02F3-B0B8-4298-B53B-8C4CD4D9D660">WARNINGS</a><span class="Bold"> SECTION).</span></p>
<div class="Section">
<a name="section-9.1"></a><p></p>
<h2>Hematologic:</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span>, <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span>, <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>.</p>
</div>
<div class="Section">
<a name="section-9.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span>:</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, allergic <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, Henoch-Schoenlein <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>-like syndrome, generalized <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin eruptions</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, conjunctival and scleral injection, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. In addition, <span class="product-label-link" type="condition" conceptid="320749" conceptname="Polyarteritis nodosa">periarteritis nodosa</span> and <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> have been reported.</p>
</div>
<div class="Section">
<a name="section-9.3"></a><p></p>
<h2>Gastrointestinal:</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> (including <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> and <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>), elevation of serum transaminase and bilirubin, <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous enterocolitis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pains</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>.</p>
</div>
<div class="Section">
<a name="section-9.4"></a><p></p>
<h2>Genitourinary:</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span>, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, BUN and serum creatinine elevation, toxic <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span> with <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> and <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, and <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span>.</p>
</div>
<div class="Section">
<a name="section-9.5"></a><p></p>
<h2>Neurologic:</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic meningitis</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuritis</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
</div>
<div class="Section">
<a name="section-9.6"></a><p></p>
<h2>Psychiatric:</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>.</p>
</div>
<div class="Section">
<a name="section-9.7"></a><p></p>
<h2>Endocrine:</h2>
<p class="First">The sulfonamides bear certain chemical similarities to some goitrogens, diuretics (acetazolamide and the thiazides) and oral hypoglycemic agents. Cross-sensitivity may exist with these agents. <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">Diuresis</span> and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> have occurred rarely in patients receiving sulfonamides.</p>
<p><span class="Bold">Musculoskeletal: </span></p>
<p><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span> and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>.</p>
</div>
<div class="Section">
<a name="section-9.8"></a><p></p>
<h2>Respiratory:</h2>
<p class="First">Pulmonary infiltrates.</p>
</div>
<div class="Section">
<a name="section-9.9"></a><p></p>
<h2>Miscellaneous:</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section">
<a name="section-10.1"></a><p></p>
<h2>Acute:</h2>
<p class="First">The amount of a single dose of sulfamethoxazole and trimethoprim that is either associated with symptoms of overdosage or is likely to be life-threatening has not been reported. Signs and symptoms of overdosage reported with sulfonamides include <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">colic</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span>. <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> and <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span> may be noted. <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">Blood dyscrasias</span> and <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> are potential late manifestations of overdosage.</p>
<p>Signs of acute overdosage with trimethoprim include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>.</p>
<p>General principles of treatment include the institution of gastric lavage or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, forcing oral fluids, and the administration of intravenous fluids if urine output is low and renal function is normal. Acidification of the urine will increase renal elimination of trimethoprim. The patient should be monitored with blood counts and appropriate blood chemistries, including electrolytes. If a significant <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasia</span> or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> occurs, specific therapy should be instituted for these complications. Peritoneal dialysis is not effective and hemodialysis is only moderately effective in eliminating sulfamethoxazole and trimethoprim.</p>
</div>
<div class="Section">
<a name="section-10.2"></a><p></p>
<h2>Chronic:</h2>
<p class="First">Use of sulfamethoxazole and trimethoprim at high doses and/or for extended periods of time may cause <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span> manifested as <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> and/or <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span>. If signs of <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span> occur, the patient should be given leucovorin 5 to 15 mg daily until normal hematopoiesis is restored.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="A590B1C4-4FA8-4D29-ABC3-5B0CCF98DBF3"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">Not recommended for use in infants less than 2 months of age. </span></p>
<div class="Section">
<a name="section-11.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span> And Shigellosis In Adults And Children And Acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span> In Children:</h2>
<div class="Section">
<a name="section-11.1.1"></a><p></p>
<h3>Adults:</h3>
<p class="First">The usual adult dosage in the treatment of <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> is 4 teaspoonfuls (20 mL) of the suspension every 12 hours for 10 to 14 days. An identical daily dosage is used for 5 days in the treatment of shigellosis.</p>
</div>
<div class="Section">
<a name="section-11.1.2"></a><p></p>
<h3>Children:</h3>
<p class="First">The recommended dose for children with <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> or acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> is 40 mg/kg sulfamethoxazole and 8 mg/kg trimethoprim per 24 hours, given in two divided doses every 12 hours for 10 days. An identical daily dosage is used for 5 days in the treatment of shigellosis. The following table is a guideline for the attainment of his dosage:</p>
<p><span class="Bold Italics">Children: 2 months of age or older</span>.</p>
<table frame="void">
<thead>
<tr class="First">
<th align="center" colspan="2" valign="top">Â Â Â Â Â  WeightÂ Â Â Â Â  </th>
<td align="center" valign="top">Dose â€“ <br>every12 hours</td>
</tr>
<tr class="Last">
<td align="center" valign="top">lb</td>
<td align="center" valign="top">kg</td>
<td align="center" valign="top">Teaspoonfuls</td>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="center" valign="top">22</td>
<td align="center" valign="top">10</td>
<td align="center" valign="top">1 (5 mL)</td>
</tr>
<tr>
<td align="center" valign="top">44</td>
<td align="center" valign="top">20</td>
<td align="center" valign="top">2 (10 mL)</td>
</tr>
<tr>
<td align="center" valign="top">66</td>
<td align="center" valign="top">30</td>
<td align="center" valign="top">3 (15 mL)</td>
</tr>
<tr class="Last">
<td align="center" valign="top">88</td>
<td align="center" valign="top">40</td>
<td align="center" valign="top">4 (20 mL)</td>
</tr>
</tbody>
</table>
<p><span class="Bold Italics">For Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span>:</span></p>
<p>When renal function is impaired, a reduced dosage should be employed using the following table:</p>
<table frame="void">
<col width="308">
<col width="308">
<thead><tr class="First Last">
<td align="center" valign="top">Creatinine Clearance (mL/min)</td>
<td align="center" valign="top">Recommended Dosage Regimen</td>
</tr></thead>
<tbody>
<tr class="First">
<td align="center" valign="top">Above 30</td>
<td align="center" valign="top">Usual standard regimen</td>
</tr>
<tr>
<td align="center" valign="top">15 - 30</td>
<td align="center" valign="top">Â½ the usual regimen</td>
</tr>
<tr class="Last">
<td align="center" valign="top">Below 15</td>
<td align="center" valign="top">Use not recommended</td>
</tr>
</tbody>
</table>
<p><span class="Bold Italics">Acute Exacerbations Of <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">Chronic Bronchitis</span> In Adults: </span></p>
<p>The usual adult dosage in the treatment of acute exacerbations of <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span> is 4 teaspoonfuls (20 mL) of the suspension every 12 hours for 14 days.</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="438350" conceptname="Pneumocystosis">Pneumocystis Carinii Pneumonia</span>: </span></p>
</div>
<div class="Section">
<a name="section-11.1.3"></a><p></p>
<h3>Treatment:</h3>
<div class="Section">
<a name="section-11.1.3.1"></a><p></p>
<h4>Adults and children:</h4>
<p class="First">The recommended dosage for treatment of patients with documented <span class="Italics">Pneumocystis carinii </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> is 75 to 100 mg/kg sulfamethoxazole and 15 to 20 mg/kg trimethoprim per 24 hours given in equally divided doses every 6 hours for 14 to 21 days.<span class="Sup">7 </span>The following table is a guideline for the upper limit of this dosage.</p>
<table frame="void">
<thead>
<tr class="First">
<th align="center" colspan="2" valign="top">Weight</th>
<td align="center" valign="top">Dose â€“ every 6 hours</td>
</tr>
<tr class="Last">
<td align="center" valign="top">lb</td>
<td align="center" valign="top">kg</td>
<td align="center" valign="top">Teaspoonfuls</td>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="center" valign="top">18</td>
<td align="center" valign="top">8</td>
<td align="center" valign="top">1 (5 mL)</td>
</tr>
<tr>
<td align="center" valign="top">35</td>
<td align="center" valign="top">16</td>
<td align="center" valign="top">2 (10 mL)</td>
</tr>
<tr>
<td align="center" valign="top">53</td>
<td align="center" valign="top">24</td>
<td align="center" valign="top">3 (15 mL)</td>
</tr>
<tr>
<td align="center" valign="top">70</td>
<td align="center" valign="top">32</td>
<td align="center" valign="top">4 (20 mL)</td>
</tr>
<tr>
<td align="center" valign="top">88</td>
<td align="center" valign="top">40</td>
<td align="center" valign="top">5 (25 mL)</td>
</tr>
<tr>
<td align="center" valign="top">106</td>
<td align="center" valign="top">48</td>
<td align="center" valign="top">6 (30 mL)</td>
</tr>
<tr>
<td align="center" valign="top">141</td>
<td align="center" valign="top">64</td>
<td align="center" valign="top">8 (40 mL)</td>
</tr>
<tr class="Last">
<td align="center" valign="top">176</td>
<td align="center" valign="top">80</td>
<td align="center" valign="top">10 (50 mL)</td>
</tr>
</tbody>
</table>
<p>For the lower limit dose (75 mg/kg sulfamethoxazole and 15 mg/kg trimethoprim per 24 hours) administer 75% of the dose in the above table.</p>
<p><span class="Bold Italics">Prophylaxis:</span></p>
<p>Adults:</p>
<p>The recommended dosage for prophylaxis in adults is 800 mg sulfamethoxazole and 160 mg trimethoprim daily.<span class="Sup">8</span></p>
<p>Children:</p>
<p>For children, the recommended dose is 750 mg/m<span class="Sup">2</span>/day sulfamethoxazole with 150 mg/m<span class="Sup">2</span>/day trimethoprim given orally in equally divided doses twice a day, on 3 consecutive days per week. The total daily dose should not exceed 1600 mg sulfamethoxazole and 320 mg trimethoprim.<span class="Sup">9</span> The following table is a guideline for the attainment of this dosage in children:</p>
<table frame="void">
<col width="319">
<col width="319">
<thead><tr class="First Last">
<td align="center" valign="top">Body Surface</td>
<td align="center" valign="top">Dose â€“ every</td>
</tr></thead>
<tbody>
<tr class="First">
<td align="center" valign="top">Area</td>
<td align="center" valign="top">12 hours</td>
</tr>
<tr>
<td align="center" valign="top">(m<span class="Sup">2</span>)</td>
<td align="center" valign="top">Teaspoonfuls</td>
</tr>
<tr>
<td align="center" valign="top">0<span class="Bold">.</span>26</td>
<td align="center" valign="top">Â½ (2<span class="Bold">.</span>5 mL)</td>
</tr>
<tr>
<td align="center" valign="top">0<span class="Bold">.</span>53</td>
<td align="center" valign="top">1 (5 mL)</td>
</tr>
<tr class="Last">
<td align="center" valign="top">1<span class="Bold">.</span>06</td>
<td align="center" valign="top">2 (10 mL)</td>
</tr>
</tbody>
</table>
<p><span class="Bold Italics">Travelersâ€™ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> In Adults: </span></p>
<p>For the treatment of travelersâ€™ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, the usual adult dosage is 4 teaspoonfuls (20 mL) of the suspension every 12 hours for 5 days.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Sulfamethoxazole and Trimethoprim Oral Suspension USP, containing 200 mg sulfamethoxazole and 40 mg trimethoprim per teaspoonful (5 mL), is a fruit-licorice flavored suspension available in pint (473 mL) bottles.</p>
<p>Sulfamethoxazole and Trimethoprim Oral Suspension USP (Pediatric), containing 200 mg sulfamethoxazole and 40 mg trimethoprim per teaspoonful (5 mL), is a cherry flavored suspension available in 100 mL and pint (473 mL) bottles.</p>
<p>Shake well before using.</p>
<p>Store at controlled room temperature 15Â°-30Â°C (59Â°-86Â°F).</p>
<p>Protect from light.</p>
<p>Dispense in a tight, light-resistant container as defined in the USP.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-13"></a><p></p>
<h1>REFERENCES</h1>
<p class="First">1. Kremers P, Duvivier J, Heusghem C. Pharmacokinetic Studies of Co-Trimoxazole in Man after Single and Repeated Doses. <span class="Italics">J. Clin Pharmacol. </span>Feb-Mar 1974; 14:112-117.</p>
<p>2. Kaplan SA, et al. Pharmacokinetic Profile of Trimethoprim-Sulfamethoxazole in Man. <span class="Italics">J Infect Dis. </span>Nov 1973; 128(Suppl): S547-S555.</p>
<p>3. <span class="Italics">Federal Register. </span>1972; 37:20527-20529.</p>
<p>4. Bauer AW, Kirby WMM, Sherris JC, Turck M. Antibiotic Susceptibility Testing by Standardized Single Disk Method. <span class="Italics">Am J Clin Path. </span>Apr 1966; 45:493-496.</p>
<p>5. Hardy DW, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of <span class="Italics">Pneumocystis carinii </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> in patients with the <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">acquired immunodeficiency syndrome</span>. <span class="Italics">N Engl J Med. </span>1992; 327:1842-1848.</p>
<p>6. Brumfitt W, Pursell R. Trimethoprim/Sulfamethoxazole in the Treatment of <span class="product-label-link" type="condition" conceptid="4265485" conceptname="Bacteriuria">Bacteriuria</span> in Women. <span class="Italics">J Infect Dis. </span>Nov. 1973; 128(Suppl): S657-S663.</p>
<p>7. Masur H. Prevention and treatment of <span class="Italics">Pneumocystis </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>. <span class="Italics">N Engl J Med. </span>1992; 327:1853-1880.</p>
<p>8. Recommendations for prophylaxis against <span class="Italics">Pneumocystis carinii </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> for adults and adolescents infected with human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus. <span class="Italics">MMWR</span>. 1992; 41(RR-4): 1-11.</p>
<p>9. CDC Guidelines for prophylaxis against <span class="Italics">Pneumocystis carinii </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> for children infected with human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus. <span class="Italics">MMWR. </span>1991; 40(RR-2);1-13.</p>
<p>Manufactured by</p>
<p>Actavis Mid Atlantic LLC</p>
<p>7205 Windsor Blvd.</p>
<p>Baltimore, MD 21244 USA</p>
<p>FORM NO. 1284/1285</p>
<p>Rev. 3/06</p>
<p>VC2785</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SULFATRIMÂ 		
					</strong><br><span class="contentTableReg">sulfamethoxazole and trimethoprim suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0472-1284</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>sulfamethoxazole</strong> (sulfamethoxazole) </td>
<td class="formItem"></td>
<td class="formItem">200Â mg Â inÂ 5Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>trimethoprim</strong> (trimethoprim) </td>
<td class="formItem"></td>
<td class="formItem">40Â mg Â inÂ 5Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>alcohol</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>carboxymethylcellulose sodium</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>citric acid</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>fd&amp;c red#40</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>fd&amp;c yellow#6</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>flavor</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>methylparaben</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>microcrystalline cellulose</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>carboxymethylcellulose sodium</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polysorbate 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>propylene glycol</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>propylparaben</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>saccharin sodium</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>simethicone emulsion</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sucrose</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">red (fruit licorice) </td>
<td class="formLabel">Score</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0472-1284-16</td>
<td class="formItem">473 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SULFATRIMÂ 		
					</strong><br><span class="contentTableReg">sulfamethoxazole and trimethoprim suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0472-1285</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>sulfamethoxazole</strong> (sulfamethoxazole) </td>
<td class="formItem"></td>
<td class="formItem">200Â mg Â inÂ 5Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>trimethoprim</strong> (trimethoprim) </td>
<td class="formItem"></td>
<td class="formItem">40Â mg Â inÂ 5Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>alcohol</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>carboxymethylcellulose sodium</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>citric acid</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>fd&amp;c red#40</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>fd&amp;c yellow#6</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>flavor</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>methylparaben</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>microcrystalline cellulose</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>carboxymethylcellulose sodium</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polysorbate 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>propylene glycol</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>propylparaben</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>saccharin sodium</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>simethicone emulsion</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sucrose</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">red (cherry flavored) </td>
<td class="formLabel">Score</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0472-1285-33</td>
<td class="formItem">100 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0472-1285-16</td>
<td class="formItem">473 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Actavis Mid Atlantic LLC</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 3/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>5D5A6260-7684-5103-84F4-86955F9BE646</div>
<div>Set id: A8DF90D8-78B3-48C3-B42E-1E651D81454B</div>
<div>Version: 2</div>
<div>Effective Time: 20090304</div>
</div>
</div>Â <div class="DistributorName">Actavis Mid Atlantic LLC</div></p>
</body></html>
